|
Match
|
Document |
Document Title |
|
|
9040511 |
3-cyano-quinoline derivatives with antiproliferative activity
The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents NH;Y... |
|
|
9040072 |
Use of coupling agents to improve the interface in absorbable polymer composites
A composite having a poly(ethylene-co-acrylic acid) coupling agent, a filler, and a biocompatible, biodegradable polymer matrix is disclosed. The composites are useful for biomedical applications... |
|
|
9040510 |
Interaction control of cationic biocides using labile anionic polyelectrolytes
Methods of inhibiting the uptake of cationic biocides into medical devices such as contact lenses and implants are described. Methods of stabilizing emulsions containing cationic biocides are also... |
|
|
9040512 |
Phosphorus-containing metal complexes
The present invention relates, inter alia, to metal complexes having improved solubility, to processes for the preparaion of the metal complexes, to devices comprising these metal complexes and to... |
|
|
9034861 |
MEK inhibitors useful in the treatment of diseases
The invention pertains to compound of Formula (I) wherein X, Y, Z, R1, R2, R3, R4, A and A′ are as described hereinabove. Formula (I) and (II) compounds can be used in pharmaceutical compositions,... |
|
|
9034860 |
Pharmaceutical composition containing low-substituted hydroxypropyl cellulose
Disclosed is a pharmaceutical composition containing a compound represented by the general formula (I) below or a pharmacologically acceptable salt thereof, while having improved dissolvability.... |
|
|
9034904 |
Forms of dexlansoprazole and processes for the preparation thereof
Provided is dexlansoprazole propylene glycolate hydrate. Polymorphic forms thereof are also provided. The dexlansoprazole propylene glycolate hydrate maybe such that the propylene glycol component... |
|
|
9029355 |
Solid ganaxolone compositions and methods for the making and use thereof
In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about... |
|
|
9023863 |
Fatty acid pharmaceutical foam
The present invention provides a foamable composition comprising water and an organic solvent, wherein the organic solvent comprises a fatty acid. The composition may further comprise a... |
|
|
9012506 |
Cross-linked fatty acid-based biomaterials
Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or... |
|
|
9012438 |
3,5,3′ -triiodothronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of... |
|
|
9012439 |
Use of electrophilic compounds for inducing platelet production or maintaining platelet function
The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet... |
|
|
9012440 |
Co-crystals of tramadol and coxibs
The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in... |
|
|
9012441 |
Therapeutic compounds
Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I,... |
|
|
9006225 |
Stable pharmaceutical composition
A pharmaceutical composition which includes a compound represented by the general formula (I): or a salt thereof, and a pharmaceutically acceptable carrier, wherein the composition does not... |
|
|
9006224 |
Neuroendocrine tumor treatment
A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug. |
|
|
9006226 |
Dihydropteridinones I
The present invention relates to dihydropteridinones, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention... |
|
|
9000040 |
Cross-linked fatty acid-based biomaterials
Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be... |
|
|
8999292 |
Methods for treating and diagnosing blinding eye diseases
This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are... |
|
|
8999965 |
Anthraquinone based near IR emitting compounds and uses thereof
Disclosed are near IR emitting fluorescent compounds; methods of making and kits containing the described compounds; and their use in fluorescence-based detection of biological materials. |
|
|
8993509 |
Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
The present invention relates to agents, and methods for identifying compounds, which agents and compounds are effective in the treatment, and more particularly, that inhibit cachexia, and its... |
|
|
8993607 |
Therapeutic compounds
The invention provides compounds of formula I, II, and III as defined herein, as well as salts thereof. The compounds may have activity as anti-proliferative agents. |
|
|
8993552 |
Compositions and methods for treatment of leukemia
The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion... |
|
|
8987242 |
Morpholinone compounds as factor IXA inhibitors
The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical... |
|
|
8987245 |
Composition and method for affecting obesity and related conditions
A method of reducing caloric intake or food intake in a mammal in need thereof. The method including delivering an effective amount of a compound comprising manganese [III] tetrakis (4-benzoic... |
|
|
8987244 |
Preventing and/or treating cardiovascular disease and/or associated heart failure
Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders... |
|
|
8987243 |
11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt
The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26triaza-tetra
-cyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,
12(27),16,21,23-decaene... |
|
|
8987323 |
Crystalline form of benzylbenzene SGLT2 inhibitor
Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of... |
|
|
8980870 |
Solid telmisartan pharmaceutical formulations
A pharmaceutical composition comprising 3 wt. % to 50 wt. % telmisartan dispersed in a dissolving matrix comprising: (a) a basic agent in a molar ratio of basic agent:telmisartan of 1:1 to... |
|
|
8980871 |
Methods of treatment for hemolysis
Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds... |
|
|
8980872 |
Agent for preventing and/or treating functional gastrointestinal disorder
A method for preventing and/or treating a functional gastrointestinal disorder, comprising administering, to a subject with the functional gastrointestinal disorder, rifaximin as an effective... |
|
|
8980873 |
11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetr
acyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,
12(27),16,21,23-decaene... |
|
|
8980874 |
Method and composition for treating diabetic ketoacidosis
Methods of treating diabetic ketoacidosis are disclosed. The methods utilize an endothelin antagonist to treat diabetic ketoacidosis in mammals, including humans. |
|
|
8975284 |
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present... |
|
|
8975247 |
Methods and compositions of treating a flaviviridae family viral infection
Clemizole and clemizole analog compounds, and pharmaceutical compositions of the same, are useful in methods of treating a host infected with a virus from the Flaviviridae family of viruses,... |
|
|
8969331 |
Treatment of skin and mucosal superficial wounds using adrenergic receptor agonists
The invention generally relates to the compositions and methods related to the use of adrenergic receptor agonists solutions for the treatment of skin and mucosal superficial wounds. Some of the... |
|
|
8969333 |
Therapeutic compositions and methods
PAD4 inhibitory compositions and methods for their use in treatment of cancer and autoimmune disease are provided according to embodiments of the present invention. |
|
|
8969332 |
Aryloxy dihalopropenyl ether compounds and uses thereof
The present invention discloses an aryloxy dihalopropenyl ether compound with the structure shown as general formula (I), of which the group definitions can be seen in the specification. The... |
|
|
8962604 |
Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl 1-pyridine-1-oxide-3-carboximidoyl chloride, the optically... |
|
|
8962606 |
Substituted benzosulphonamides
The present invention relates to substituted benzosulphonamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said... |
|
|
8962605 |
Polycyclic compounds, termed calixurenes, and uses thereof
Disclosed is a novel family of macrocyclic compounds, coined calixurenes, which comprises linear and cyclic oligomers composed of alternating moieties of an aromatic unit and a ureatic unit,... |
|
|
8957107 |
Method of treating scars and β-catenin-mediated disorders using Nefopam compounds
Methods of treating disorders mediated by β-catenin comprising administration of Nefopam compounds are provided In particular, the treatment of disorders arising from excessive or undesired... |
|
|
8957056 |
Migrastatin analogs in the treatment of cancer
In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula... |
|
|
8957057 |
Use of azaphilone compounds for the modulation of the activity of a nuclear hormone receptor
The present invention concerns the uses of an azaphilone compound of formula (I): formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification for modulation... |
|
|
8951997 |
Substituted isoquinoline derivative
The present invention provides an isoquinoline-6-sulfonamide derivative that is useful as a novel pharmaceutical agent. The present invention provides an isoquinoline-6-sulfonamide derivative... |
|
|
8951998 |
Quinoxaline-containing compounds as hepatitis C virus inhibitors
The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity... |
|
|
8952029 |
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant... |
|
|
8951969 |
Compositions and methods for treating centrally mediated nausea and vomiting
Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery. |
|
|
8945627 |
Micelles for the solubilization of gossypol
The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and... |
|
|
8946251 |
Method of treating thermoregulatory dysfunction with paroxetine
The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally... |